Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - January 2016

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Aripiprazole - Tablets, Orally Disintegrating Tablets, Oral Solution, and Injection for INTRAMUSCULAR USE ONLY
Aripiprazole - for Extended-release Injectable Suspension, for Intramuscular Use
Carbachol - Intraocular solution, USP
Carfilzomib - for Injection
Clindamycin - Solution, Lotion, and Gel, 1 Percent
Enalapril - 1 mg/mL Powder (reconstituted) for Oral Solution
Eribulin mesylate - Injection
Golimumab - Injection
Golimumab - Injection, for Intravenous Infusion
Hyaluronidase - Human Injection
Ibuprofen - lysine Solution
Iloperidone - Tablets
Lomustine - Capsules
OnabotulinumtoxinA
Pentoxifylline - Tablets
Pramipexole - Tablets
Pramipexole- Extended-Release Tablets
Propylthiouracil - Tablets
Ranolazine - Extended-Release Tablets
Topotecan - Injection
Trandolapril - Tablets
Treprostinil - Extended Release Tablets

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Complete Hypertension Guide: Control, Causes and Prevention.
Stay Connected
Available on the Android Market Available on the App Store

Home

Consult

e-Book

Articles

News

Calculators

Drugs

Directories

Education